Telix Pharmaceuticals to Acquire ITM Isotope Technologies for $1.65 Billion

Australian radiopharmaceutical company Telix Pharmaceuticals (ASX:TLX) has agreed to acquire Germany’s ITM Isotope Technologies Munich in a deal with an upfront consideration of $1.65 billion. The acquisition is a strategic move to secure and vertically integrate Telix's supply chain for critical medical radioisotopes used in cancer treatments.

Deal Structure

Under the terms announced by the company, the transaction is comprised of several key components:

• An upfront payment of approximately $1.25 billion in Telix shares.
• The assumption of $302 million in ITM's net debt and other transaction-related costs.
• A potential additional consideration of up to $700 million, contingent on regulatory approvals and future sales milestones for ITM's lead drug candidate, ITM-11.

Following the transaction, ITM shareholders are set to receive 105.8 million Telix shares. The company stated that existing Telix shareholders will own approximately 76.3% of the combined entity.

Strategic Rationale

Ad

The acquisition provides Telix with direct control over a major supplier of therapeutic radioisotopes, including lutetium-177, actinium-225, and terbium-161. Munich-based ITM operates a global distribution network that spans more than 65 countries, providing a crucial infrastructure for the radiopharmaceutical industry.

ITM has demonstrated significant growth, with reported revenues of $273 million in 2025. According to the announcement, this represents a compound annual growth rate (CAGR) of 40% since 2021. The deal also incorporates ITM's late-stage drug pipeline, which is headlined by ITM-11, a treatment candidate for gastroenteropancreatic neuroendocrine tumors that has completed a Phase 3 trial.

Outlook and Timeline

For investors, this transaction signals a consolidation within the specialized radiopharmaceutical sector, combining Telix's therapeutic and diagnostic development with ITM's established production and supply capabilities. The deal is expected to enhance Telix's market position and de-risk its supply chain for future product launches.

The transaction is subject to shareholder and regulatory approvals and is anticipated to close by the end of 2026.